← Browse by Condition
Medical Condition
chronic graft vs host disease
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 4
NCT06824103 Phase 4
Recruiting
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
Enrollment
50 pts
Location
China
Sponsor
Novartis Pharmaceuticals
NCT00092235
Recruiting
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
Enrollment
650 pts
Location
United States
Sponsor
National Cancer Institute (NCI...